Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter twenty twenty six Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you would need to press 11 on your telephone. You would then hear an automated message advising your hand is raised. We ask that you please limit to one question and return to the queue for additional questions. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Chad Fugert, Vice President of Investor Relations. Please go ahead. Thank you, operator, and thank you, everyone, for joining our second quarter twenty twenty six financial results conference call. I'm Chad Fugere, Vice President, Investor Relations at Ascendis Pharma. Joining me on the call today are Jen Mickelson, President and Chief Executive Officer Scott Smith, Chief Financial Officer Sherry Glass, Chief Business Officer and Jay Wu, Executive Vice President and President, Ascendis U. S. We begin, I'd like to remind you that this conference call, including the Q and A session that follows our prepared remarks, will contain forward looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. All statements made on this call other than the statements of historical fact are forward looking statements. Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SKYYTORAFA, Yorvipath and UbWell, including label expansion and combination treatment certain expectations regarding patient access and finan...